Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
About this item
Full title
Author / Creator
Vinet, Mathilde , Suresh, Samyuktha , Maire, Virginie , Monchecourt, Clarisse , Némati, Fariba , Lesage, Laetitia , Pierre, Fabienne , Ye, Mengliang , Lescure, Auriane , Brisson, Amélie , Meseure, Didier , Nicolas, André , Rigaill, Guillem , Marangoni, Elisabetta , Del Nery, Elaine , Roman‐Roman, Sergio and Dubois, Thierry
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
TNBC is a highly heterogeneous and aggressive breast cancer subtype associated with high relapse rates, and for which no targeted therapy yet exists. Protein arginine methyltransferase 5 (PRMT5), an enzyme which catalyzes the methylation of arginines on histone and non‐histone proteins, has recently emerged as a putative target for cancer therapy....
Alternative Titles
Full title
Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e38d40999951432e94d1e8844dc31f54
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e38d40999951432e94d1e8844dc31f54
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.2114
